Pyridone derivatives as potent, orally bioavailable VLA-4 integrin antagonists

Bioorganic and Medicinal Chemistry Letters

Volumn 16, Issue 21, 2006, Pages 5538-5541

  Witherington, Jason ^a   Blaney, Emma L ^a   Bordas, Vincent ^a   Elliott, Richard L ^a   Gaiba, Alessandra ^a   Garton, Neil ^a   Green, Philip M ^a   Naylor, Antoinette ^a   Smith, David G ^a   Spalding, David J ^a   Takle, Andrew K ^a   Ward, Robert W ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Bioavailability; Integrin; Pyridone; VLA 4

Indexed keywords

PYRIDONE DERIVATIVE; VERY LATE ACTIVATION ANTIGEN 4;

ANIMAL EXPERIMENT; ARTICLE; DRUG BIOAVAILABILITY; DRUG POTENCY; NONHUMAN; RAT;

ADMINISTRATION, ORAL; ANIMALS; INTEGRIN ALPHA4BETA1; PYRIDONES; RATS;

EID: 33748849080     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.08.044     Document Type: Article

References (20)

1. Hemler M.E., Elices M.J., Parker C., and Takada Y. Immunol. Rev. 114 (1990) 45
2. Springer T.A. Cell 76 (1994) 301
3. Elices M.J. Curr. Opin. Anti-Inflam. Immunomod. Invest. Drugs 1 (1999) 14
4. Gearing A.J.H., and Newman W. Immunol. Today 14 (1993) 506
5. Hemler M.E. Annu. Rev. Immunol. 8 (1990) 365
6. Abraham W.M., Sielczak M.W., Ahmed A., Cortes A., Lauredo I.T., Kim J., Pepinsky B., Benjamin C.D., Leone D.R., and Lobb R.R. J. Clin. Invest. 93 (1994) 776
7. Seiffge D. J. Rheumatol. 23 (1996) 2086
8. Tubridy N., Behan P.O., Caplildeo R., Chaudhuri A., Forbes R., Hawkins C.P., Hughes R.A.C., Palace J., Sharrack B., Swingler R., Young C., Mosley I.F., MacManus D.G., Donoghue S., and Miller D.H. Neurology 53 (1999) 466
9. Keszthelyi E., Karlik S., Hyduk S., Rice A., Gordon G., Yednock T., and Horner H. Neurology 47 (1996) 1053
10. Podolsky D.K., Lobb R., King N., Benjamin C.D., Pepinsky B., Sehgal P., and deBaumont M. J. Clin. Invest. 92 (1993) 972
11. Polman C.H., O'Connor P.W., Havrdova E., Hutchinson M., Kappos L., Miller D.H., Phillips J.T., Lublin F.D., Giovannoni G., Wajgt A., Toal M., Lynn F., Panzara M.A., and Sandrock A.W. N. Engl. J. Med. 354 (2006) 899
12. Sandborn W.J., Colombel J.F., Enns R., Feagan B.G., Hanauer S.B., Lawrance I.C., Panaccione R., Sanders M., Schreiber S., Targan S., van Deventer S., Goldblum R., Despain D., Hogge G.S., and Rutgeerts P. N. Engl. J. Med. 353 (2005) 1912
13. Witherington J., Bordas V., Gaiba A., Green P.M., Naylor A., Parr N., Smith D.G., Takle A.K., and Ward R.W. Bioorg. Med. Chem. Lett. 16 (2006) 2256
14. Lin K.-C., Ateeq H.S., Hsiung S.H., Chong L.T., Zimmerman C.N., Castro A., Lee W.-C., Hammond C.E., Kalkunte S., Chen L.-L., Pepinsky R.B., Leone D.R., Sprague A.G., Abraham W.M., Gill A., Lobb R.R., and Adams S.P. J. Med. Chem. 42 (1999) 920
15. Singh J., Vlihmen H.V., Liao Y., Lee W.-C., Corbenise M., Harris M., Shu I.-H., Gill A., Cuervo J.H., Abraham W.M., and Adams S.P. J. Med. Chem. 45 (2002) 2988
16. Chiba J., Takayama G., Takashi T., Yokoyama M., Nakayama, Baldwin J.J., McDonald E., Moriarty K.J., Sarko C.R., Saionz K.W., Swanson R., Hussain Z., Wong A., and Machinaga N. Bioorg. Med. Chem. 14 (2006) 2725
17. i. Standard compound A is (2S)-3-[4-({[4-(aminocarbonyl)-1-piperidinyl]carbonyl}oxy)phenyl]-2-[((2 S)-4-methyl-2-{[2-(2-methylphenoxy)acetyl]amino}pentanoyl)amino] propanoic acid potassium salt which is described in patent application WO 00/37444.
18. Witherington, J; Elliot, R. L. JP 2005255675.
19. Witherington, J; Elliot, R. L. WO 2004014859.
20. DeGraw J.I., Christie P.H., Tagawa H., Kisliuk R.L., Gaumont Y., Schmid F.A., and Sirotnak F.M. J. Med. Chem. 29 (1986) 1056